Regeneron Pharmaceuticals Earnings: Here’s Why Investors are Selling Shares Now

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 4.51%.

Regeneron Pharmaceuticals, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased 147.14% to $1.73 in the quarter versus EPS of $0.70 in the year-earlier quarter.

Revenue: Rose 50.33% to $457.6 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Regeneron Pharmaceuticals, Inc. reported adjusted EPS income of $1.73 per share. By that measure, the company beat the mean analyst estimate of $0.88. It missed the average revenue estimate of $473.23 million.

Quoting Management: “We are pleased with these positive data in another potentially important indication for EYLEA,” said George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. “Diabetes is a growing disease worldwide and DME is a major cause of vision loss in people with diabetic retinopathy. We hope to be able to offer a new treatment option for patients suffering from this potentially blinding retinal disease.”

Key Stats (on next page)…

Revenue increased 4.08% from $439.66 million in the previous quarter. EPS increased 92.22% from $0.90 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $1.08 to a profit $0.99. For the current year, the average estimate has moved up from a profit of $3.91 to a profit of $3.95 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]